Literature DB >> 29180095

Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.

Jorge R Georgakopoulos1, Arvin Ighani2, Michelle Phung3, Jensen Yeung4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29180095     DOI： 10.1016/j.jaad.2017.11.036

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  9 in total

1.  When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.

Authors:  Giovanni Damiani; Rosalynn R Z Conic; Valerio de Vita; Antonio Costanzo; Roberto Regazzini; Paolo D M Pigatto; Nicola L Bragazzi; Alessia Pacifico; Piergiorgio Malagoli
Journal:  Dermatol Ther       Date:  2018-12-21       Impact factor: 2.851

2.  Changes in metabolic parameters in psoriatic patients treated with secukinumab.

Authors:  Hsuan Ning Wang; Yu Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2020-08-03       Impact factor: 5.091

3.  Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

Authors:  Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo
Journal:  Acta Derm Venereol       Date:  2021-10-21       Impact factor: 3.875

4.  Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.

Authors:  Tzong-Yun Ger; Yu-Huei Huang; Rosaline Chung-Yee Hui; Tsen-Fang Tsai; Hsien-Yi Chiu
Journal:  Ther Adv Chronic Dis       Date:  2019-04-17       Impact factor: 5.091

5.  Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy.

Authors:  Giuseppe Argenziano; Luca Bianchi; Paolo Amerio; Maria Grazia Aragone; Ginevra Baggini; Manuela Baldari; Gianpiero Castelli; Simmaco Coppola; Antonio Costanzo; Rocco De Pasquale; Maria Concetta Fargnoli; Caterina Foti; Claudia Giofrè; Serena Lembo; Claudia Leporati; Francesco Loconsole; Giovanna Malara; Ketty Peris; Antonio Giovanni Richetta; Paola Savoia; Rossana Tiberio; Massimo Travaglini; Maria Teresa Uzzauto
Journal:  Patient Prefer Adherence       Date:  2021-11-19       Impact factor: 2.711

Review 6.  Role of Fetuin-A in the Pathogenesis of Psoriasis and Its Potential Clinical Applications.

Authors:  Endeshaw Chekol Abebe; Zelalem Tilahun Muche; Awgichew Behaile T/Mariam; Teklie Mengie Ayele; Melaku Mekonnen Agidew; Muluken Teshome Azezew; Edgeit Abebe Zewde; Tadesse Asmamaw Dejenie
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-08

7.  Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.

Authors:  Rani Soenen; Zhigang Wang; Lynda Grine; Erwin Dreesen; Lisa Schots; Els Brouwers; Paul Declerck; Debby Thomas; Jo Lambert
Journal:  Clin Exp Dermatol       Date:  2022-04-25       Impact factor: 4.481

8.  Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study.

Authors:  Ilteris Oguz Topal; Sevim Baysak; İlknur Kıvanç Altunay; Asude Kara Polat; Eylem Emel Arıkan; Ezgi Özkur; Sema Aytekin; Bilal Dogan; Tuğba Özkök Akbulut; Filiz Topaloğlu Demir; Ayşe Serap Karadağ
Journal:  An Bras Dermatol       Date:  2022-07-15       Impact factor: 2.113

9.  Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).

Authors:  Peter Foley; Nick Manuelpillai; Con Dolianitis; Geoffrey D Cains; Eric Mate; Rebecca Tronnberg; Christopher Baker
Journal:  Australas J Dermatol       Date:  2022-07-09       Impact factor: 2.481
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.